RHEI Pharmaceuticals has begun the final China clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system. Tibozole will attempt to approve its efficacy as a treatment for oral candidiasis, a condition that affects immuno-compromised patients with HIV/AIDS and cancer patients undergoing chemotherapy. RHEI, a venture-backed company, has offices in the US and Belgium, but its operations are in China. More details.

Stock Symbols: (NYSE: JNJ) (NSDQ: APPA)